Glenmark Pharmaceuticals Ltd. has achieved a major milestone in its global expansion strategy with approval of its respiratory treatment product, RYALTRIS®, by China’s National Medical Products Administration (NMPA). This approval reinforces Glenmark’s leadership in respiratory innovation and expands its footprint in the Chinese pharmaceutical market.
Key Highlights of the Approval
Product: RYALTRIS® Compound Nasal Spray (GSP 301 NS)
Indication: Treatment of Allergic Rhinitis (AR) in adults and children
Specific Approvals:
Moderate to severe seasonal AR in adults and children aged 6 years and older
Moderate to severe perennial AR in adults and children aged 12 years and older
Clinical Trial Success in China
The NMPA approval follows the successful completion of a Phase III clinical trial (GSP 301-308) conducted across multiple centers in China with 535 patients. The trial demonstrated RYALTRIS®’s superior efficacy compared to monotherapy alternatives, confirming its value for patients with allergic rhinitis.
Expanding Global Footprint
RYALTRIS® has already secured approvals in key markets including:
*United States
*European Union
*United Kingdom
*Australia
*South Korea
*Russia
The product has been launched in eleven international markets, bringing its global presence to 45 countries, highlighting Glenmark’s commitment to delivering innovative respiratory solutions worldwide.
Strategic Partnership in China
To support commercialization, Glenmark has entered an exclusive licensing agreement with Grand Pharmaceuticals Group Limited. This partnership underscores Glenmark’s focus on strategic collaborations to accelerate market access and reach patients and healthcare professionals efficiently.
Management Commentary
Christoph Stoller, President and Business Head – Europe and Emerging Markets, Glenmark Pharmaceuticals Ltd., stated, “The approval of RYALTRIS® in China is a significant step in expanding our specialty respiratory portfolio. China is a priority market for Glenmark, and together with Grand Pharmaceuticals, our focus is on enabling access to this treatment for patients and healthcare professionals.”
Driving Innovation and Growth
The approval not only strengthens Glenmark’s position in the respiratory innovation space but also aligns with the company’s global strategy to expand its specialty product portfolio. As reported by scanx.trade, as Glenmark advances its innovative therapies for chronic conditions, the Chinese market presents substantial opportunities for growth, patient impact, and long-term business expansion.
